Rationale and design of INFINITY-SWEDEHEART: A registry-based randomized clinical trial comparing clinical outcomes of the sirolimus-eluting DynamX bioadaptor to the zotarolimus-eluting Resolute Onyx stent.
David ErlingeJonas AnderssonOle FröbertMattias TörnerudFelix BöhmClaes HeldCandace ElekMotasim SirhanJonas OldgrenStefan JamesPublished in: American heart journal (2024)
The INFINITY-SWEDEHEART study is designed to evaluate the long-term safety and efficacy of the DynamX bioadaptor compared to the Resolute Onyx stent in a general PCI patient population.